Cardiovascular outcomes trials of SGLT-2 inhibitors pointed to significant benefits for kidney outcomes in type 2 diabetes, findings that were subsequently supported by real-world observational data. This module takes a closer look at what lies behind such benefits and reports results from three trials specifically designed to investigate the renal outcomes of treatment with SGLT-2 inhibitors: CREDENCE, DAPA-CKD and EMPA-KIDNEY.
Assessment will rely in part on learners having read the following article referenced in this module.
By the end of this module, you will be able to:
✓ Explain the mechanisms that underlie the renal benefits seen when people with type 2 diabetes are treated with SGLT-2 inhibitors
✓ Analyse the clinical trial evidence demonstrating that SGLT-2 inhibitors can prevent chronic kidney disease, as well as improve cardiovascular outcomes in people with type 2 diabetes
✓ Plan the clinical management of people with type 2 diabetes and diabetic kidney disease, considering the evidence from current clinical trials and EASD/ADA guidelines
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.